Journal of Clinical Oncology
Articles in this Issue
First-line (1L) trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.
4022 Background: T-DXd 6.4 mg/kg monotherapy is approved in several countries for advanced HER2+ (IHC 3+ or IHC 2+/ISH+) G...
Dose-escalation results from a phase I study of FZ-AD004, a TROP2-directed ADC, in patients with advanced solid tumors.
8523 Background: FZ-AD004 is an ADC (antibody-drug conjugate) targeting Trop-2 (trophoblast cell-surface antigen 2), an in...
Mortality trends and disparities in prostate cancer with co-occurring cardiometabolic disorders among U.S. men aged ≥ 55 years, 1999–2024.
5061 Background: Prostate cancer (PCa) survivors are at significant risk for cardiometabolic disorders (CMD) including hyp...
Transfer of care after virtual oncology second opinions.
e23212 Background: Virtual oncology second opinions have expanded access to subspecialty expertise, potentially reducing g...
Real-world feasibility and tolerability of Pedmark for otoprotection in young adults receiving cisplatin for solid tumors.
e24189 Background: Cisplatin-induced ototoxicity is an irreversible toxicity that affects up to 90% of patients, with part...
BRIDGES: A phase 3 randomized trial of immediate postoperative cesium-131 tile-based radiation therapy followed by abbreviated chemoradiation for newly diagnosed glioblastoma (NCT07195591).
TPS2105 Background: Glioblastoma remains a lethal primary brain tumor with limited therapeutic progress and a persistent u...
Comparing oncologists, a GPT-based model, and a SEER-based survival calculator for cancer prognostication.
1621 Background: Prognostic estimates guide cancer treatment planning and goals-of-care discussions. Clinicians often rely...
Long-term comparative risk of cardiovascular complications in patients receiving immune checkpoint inhibitors versus traditional chemotherapy: A real-world TriNetX analysis.
e24034 Background: Immune checkpoint inhibitors (ICIs) have transformed cancer care and expand across combination regimens...
Changes and significance of immune-related indicators in patients with recurrent/metastatic nasopharyngeal carcinoma before and after PD-1 inhibitor combined with GP regimen chemotherapy.
e18036 Background: To investigate the dynamic changes of peripheral blood immune-related indicators and their association...
Deep learning–based computer-aided detection and diagnosis system for malignant biliary stricture (with videos).
e16007 Background: Timely and precise diagnosis of malignant biliary stricture (MBS) remains challenging. Although digital...
Understanding underuse of radiation therapy in older adults with high-risk prostate cancer.
e17017 Background: Radiation therapy (RT) is a cornerstone of curative treatment for high-risk prostate cancer. However, o...
Triple-negative breast cancer: Real-world evidence from a national oncologic reference center in Panama.
e13117 Background: Triple-negative breast cancer (TNBC) accounts for 10–15% of breast cancers and is associated with aggre...
Improving timely antibiotic administration in febrile neutropenia: A quality improvement initiative in a tertiary oncology hospital.
e24152 Background: Febrile neutropenia (FN) defined as (100.4 degree F sustained for 1 hour ) with an absolute neutrophil...
Adjunctive and post-transplant doxycycline in systemic light-chain (AL) amyloidosis.
e19551 Background: Systemic immunoglobulin light-chain (AL) amyloidosis has high early mortality. Doxycycline has been ado...
Impact of regorafenib treatment on overall survival (OS) in advanced sarcoma patients.
11556 Background: Regorafenib has been evaluated in several sarcoma clinical trials and the common primary endpoint of the...
Nintedanib in advanced solid tumors: A meta-analysis of randomized controlled trials.
e15170 Background: Nintedanib (Vargatef/BIBF 1120) is an anti-angiogenic tyrosine kinase inhibitor evaluated across multip...
Nationwide trends, hospital volume, and drivers of survey-weighted 30-day unplanned readmission after pancreatic resection (NRD 2016–2022).
e16341 Background: National, survey-weighted benchmarking of 30-day unplanned readmission after pancreatic resection and i...
Use of parsimonious Fitbit step metrics to improve frailty classification in adults ≥50 with cancer in NIH All of Us.
1657 Background: Frailty predicts treatment intolerance and adverse outcomes in older adults with cancer, yet scalable scr...
Concordance of Ki-67 index and histologic grade between biopsy and surgical specimens in breast cancer: Implications of treatment decision-making.
e12593 Background: The Ki-67 index and histologic grade are key pathological features guiding systemic treatment decisions...
Evolving management of advanced-stage, resectable cutaneous squamous cell carcinoma.
e14582 Background: Patients (pts) with advanced-stage, resectable cutaneous squamous cell carcinoma (CSCC) have historical...
Comparison of longitudinal circulating tumor DNA (ctDNA) and carcinoembryonic antigen (CEA) for post-operative risk stratification in colorectal cancer (CRC).
3637 Background: ctDNA is a reliable biomarker that outperforms CEA for detecting molecular residual disease in CRC. Howev...
Role of adjuvant pembrolizumab in resected stage III melanoma: Real-world evidence from a Peruvian reference center.
e21546 Background: Stage III melanoma carries a high risk of recurrence after surgery. Adjuvant pembrolizumab has demonstr...
Oncomovies: Cancer in cinema from early sound film to 2025.
9023 Background: Cinema has played a relevant role in shaping public representations of cancer, influencing social percept...
cfDNA-based signatures of nucleosome organization to enable prostate cancer subtyping.
5130 Background: Neuroendocrine prostate cancer (NEPC) can arise from prostate adenocarcinoma (PRAD) via therapy-associate...
TACE/HAIC combined with bevacizumab and tislelizumab as third-line therapy for colorectal cancer with unresectable liver metastases: A prospective, observational real-world study (TABTiC).
e15617 Background: Microsatellite stable (MSS) colorectal cancer (CRC) with unresectable liver metastases has limited effe...